| abstract |
The use of a combination of (a) at least one abl- receptor inhibitor, PDGF-R- (platelet-derived growth factor receptor) and / or receptor tyrosine kinase kit and (b) at least one organic compound capable of binding to the acid glycoprotein-alpha 1, wherein any component (a) and / or (b) may also be present in the form of a pharmaceutically acceptable salt, if at least one group forming a salt is present , to produce a pharmaceutical preparation for use as compositions against a proliferative disease that can be treated by administration of an inhibitor of the abl- receptor, PDGF-R- and / or tyrosine kinase kit receptor, which or, during the treatment with 4- (4-methylpiperazin-1-ylmethyl) -N- [4-methyl-3- (4-pyridin-3-yl) pyrimidin-2-ylamino) phenyl] benzamide, is converted or becomes complete or partially resistant to said treatment. |